# AET01_AESI Variant 1 works as expected

    Code
      res
    Output
                                                                                       Placebo     Xanomeline High Dose   Xanomeline Low Dose
                                                                                        (N=86)            (N=72)                (N=96)       
      ———————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————
      Total number of patients with at least one AE                                   69 (80.2%)        70 (97.2%)            86 (89.6%)     
      Total number of AEs                                                                301               436                    454        
      Total number of patients with at least one AE by worst grade                                                                           
        Grade 1                                                                       22 (25.6%)        18 (25.0%)            19 (19.8%)     
        Grade 2                                                                       24 (27.9%)        19 (26.4%)            35 (36.5%)     
        Grade 3                                                                        8 (9.3%)         16 (22.2%)            11 (11.5%)     
        Grade 4                                                                       12 (14.0%)        16 (22.2%)            19 (19.8%)     
        Grade 5 (fatal outcome)                                                        3 (3.5%)          1 (1.4%)              2 (2.1%)      
      Total number of patients with study drug withdrawn due to AE                        0                 0                      0         
      Total number of patients with dose modified/interrupted due to AE                   0                 0                      0         
      Total number of patients with treatment received for AE                         69 (80.2%)        70 (97.2%)            86 (89.6%)     
      Total number of patients with all non-fatal AEs resolved                         6 (7.0%)          3 (4.2%)              6 (6.2%)      
      Total number of patients with at least one unresolved or ongoing non-fatal AE   63 (73.3%)        67 (93.1%)            80 (83.3%)     
      Total number of patients with at least one serious AE                               0              1 (1.4%)              2 (2.1%)      
      Total number of patients with at least one related AE                               0                 0                      0         

# AET01_AESI Variant 2 works as expected

    Code
      res
    Output
                                                                                          Placebo     Xanomeline High Dose   Xanomeline Low Dose
                                                                                           (N=86)            (N=72)                (N=96)       
      ——————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————
      Total number of patients with at least one AE                                      69 (80.2%)        70 (97.2%)            86 (89.6%)     
      Total number of AEs                                                                   301               436                    454        
      Total number of patients with at least one AE by worst grade                                                                              
        Grade 1                                                                          22 (25.6%)        18 (25.0%)            19 (19.8%)     
        Grade 2                                                                          24 (27.9%)        19 (26.4%)            35 (36.5%)     
        Grade 3                                                                           8 (9.3%)         16 (22.2%)            11 (11.5%)     
        Grade 4                                                                          12 (14.0%)        16 (22.2%)            19 (19.8%)     
        Grade 5 (fatal outcome)                                                           3 (3.5%)          1 (1.4%)              2 (2.1%)      
      Total number of patients with study drug withdrawn due to AE                           0                 0                      0         
      Total number of patients with dose modified/interrupted due to AE                      0                 0                      0         
      Total number of patients with treatment received for AE                            69 (80.2%)        70 (97.2%)            86 (89.6%)     
      Total number of patients with all non-fatal AEs resolved                            6 (7.0%)          3 (4.2%)              6 (6.2%)      
        No. of patients with study drug withdrawn due to resolved AE                         0                 0                      0         
        No. of patients with dose modified/interrupted due to resolved AE                    0                 0                      0         
        No. of patients with treatment received for resolved AE                           6 (7.0%)          3 (4.2%)              6 (6.2%)      
      Total number of patients with at least one unresolved or ongoing non-fatal AE      63 (73.3%)        67 (93.1%)            80 (83.3%)     
        No. of patients with study drug withdrawn due to unresolved or ongoing AE            0                 0                      0         
        No. of patients with dose modified/interrupted due to unresolved or ongoing AE       0                 0                      0         
        No. of patients with treatment received for unresolved or ongoing AE             63 (73.3%)        67 (93.1%)            80 (83.3%)     
      Total number of patients with at least one serious AE                                  0              1 (1.4%)              2 (2.1%)      
        No. of patients with study drug withdrawn due to serious AE                          0                 0                      0         
        No. of patients with treatment received for serious AE                               0                 0                      0         
        No. of patients with dose modified/interrupted due to serious AE                     0              1 (1.4%)              2 (2.1%)      
      Total number of patients with at least one related AE                                  0                 0                      0         
        No. of patients with study drug withdrawn due to related AE                          0                 0                      0         
        No. of patients with dose modified/interrupted due to related AE                     0                 0                      0         
        No. of patients with treatment received for related AE                               0                 0                      0         
        No. of patients with serious, related AE                                             0                 0                      0         

# AET01_AESI Variant 3 works as expected

    Code
      res
    Output
                                                                                                            Placebo     Xanomeline High Dose   Xanomeline Low Dose
                                                                                                             (N=86)            (N=72)                (N=96)       
      ————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————
      Total number of patients with at least one AE                                                        69 (80.2%)        70 (97.2%)            86 (89.6%)     
      Total number of AEs                                                                                     301               436                    454        
      Total number of patients with at least one AE by worst grade                                                                                                
        Grade 1                                                                                            22 (25.6%)        18 (25.0%)            19 (19.8%)     
        Grade 2                                                                                            24 (27.9%)        19 (26.4%)            35 (36.5%)     
        Grade 3                                                                                             8 (9.3%)         16 (22.2%)            11 (11.5%)     
        Grade 4                                                                                            12 (14.0%)        16 (22.2%)            19 (19.8%)     
        Grade 5 (fatal outcome)                                                                             3 (3.5%)          1 (1.4%)              2 (2.1%)      
      Total number of patients with study drug 1 withdrawn due to AE                                           0                 0                      0         
      Total number of patients with study drug 2 withdrawn due to AE                                           0                 0                      0         
      Total number of patients with dose of study drug 1 modified/interrupted due to AE                        0                 0                      0         
      Total number of patients with dose of study drug 2 modified/interrupted due to AE                        0                 0                      0         
      Total number of patients with treatment received for AE                                              69 (80.2%)        70 (97.2%)            86 (89.6%)     
      Total number of patients with all non-fatal AEs resolved                                              6 (7.0%)          3 (4.2%)              6 (6.2%)      
        No. of patients with study drug 1 withdrawn due to resolved AE                                         0                 0                      0         
        No. of patients with study drug 2 withdrawn due to resolved AE                                         0                 0                      0         
        No. of patients with dose of study drug 1 modified/interrupted due to resolved AE                      0                 0                      0         
        No. of patients with dose of study drug 2 modified/interrupted due to resolved AE                      0                 0                      0         
        No. of patients with treatment received for resolved AE                                             6 (7.0%)          3 (4.2%)              6 (6.2%)      
      Total number of patients with at least one non-fatal unresolved or ongoing AE                        63 (73.3%)        67 (93.1%)            80 (83.3%)     
        No. of patients with study drug 1 withdrawn due to unresolved or ongoing AE                            0                 0                      0         
        No. of patients with study drug 2 withdrawn due to unresolved or ongoing AE                            0                 0                      0         
        No. of patients with dose of study drug 1 modified/interrupted due to unresolved or ongoing AE         0                 0                      0         
        No. of patients with dose of study drug 2 modified/interrupted due to unresolved or ongoing AE         0                 0                      0         
        No. of patients with treatment received for unresolved or ongoing AE                               63 (73.3%)        67 (93.1%)            80 (83.3%)     
      Total number of patients with at least one serious AE                                                    0              1 (1.4%)              2 (2.1%)      
        No. of patients with study drug 1 withdrawn due to serious AE                                          0                 0                      0         
        No. of patients with study drug 2 withdrawn due to serious AE                                          0                 0                      0         
        No. of patients with dose of study drug 1 modified/interrupted due to serious AE                       0                 0                      0         
        No. of patients with dose of study drug 2 modified/interrupted due to serious AE                       0                 0                      0         
        No. of patients with treatment received for serious AE                                                 0              1 (1.4%)              2 (2.1%)      
      Total number of patients with at least one AE related to study drug 1                                    0                 0                      0         
        No. of patients with study drug 1 withdrawn due to AE related to study drug 1                          0                 0                      0         
        No. of patients with study drug 1 withdrawn due to AE related to study drug 2                          0                 0                      0         
        No. of patients with dose of study drug 1 modified/interrupted due to AE related to study drug 1       0                 0                      0         
        No. of patients with dose of study drug 1 modified/interrupted due to AE related to study drug 2       0                 0                      0         
        No. of patients with treatment received for AE related to study drug 1                                 0                 0                      0         
        No. of patients with serious AE related to study drug 1                                                0                 0                      0         
      Total number of patients with at least one AE related to study drug 2                                    0                 0                      0         
        No. of patients with study drug 2 withdrawn due to AE related to study drug 1                          0                 0                      0         
        No. of patients with study drug 2 withdrawn due to AE related to study drug 2                          0                 0                      0         
        No. of patients with dose of study drug 2 modified/interrupted due to AE related to study drug 1       0                 0                      0         
        No. of patients with dose of study drug 2 modified/interrupted due to AE related to study drug 2       0                 0                      0         
        No. of patients with treatment received for AE related to study drug 2                                 0                 0                      0         
        No. of patients with serious AE related to study drug 2                                                0                 0                      0         

# AET01_AESI Variant 4 works as expected

    Code
      res
    Output
                                                                                        A: Drug X    B: Placebo   C: Combination
      Standardized MedDRA Query                                                          (N=134)      (N=134)        (N=132)    
      ——————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————
      C.1.1.1.3/B.2.2.3.1 AESI (BROAD)                                                                                          
        Total number of patients with at least one AE                                   58 (43.3%)   60 (44.8%)     66 (50.0%)  
        Total number of AEs                                                                 97          106            122      
        Total number of patients with at least one AE by worst grade                                                            
          Grade 1                                                                       22 (16.4%)   26 (19.4%)     30 (22.7%)  
          Grade 2                                                                           0            0              0       
          Grade 3                                                                           0            0              0       
          Grade 4                                                                       36 (26.9%)   34 (25.4%)     36 (27.3%)  
          Grade 5 (fatal outcome)                                                           0            0              0       
        Total number of patients with study drug withdrawn due to AE                     5 (3.7%)     6 (4.5%)       9 (6.8%)   
        Total number of patients with dose modified/interrupted due to AE               21 (15.7%)   21 (15.7%)     24 (18.2%)  
        Total number of patients with treatment received for AE                         32 (23.9%)   35 (26.1%)     44 (33.3%)  
        Total number of patients with all non-fatal AEs resolved                         7 (5.2%)     9 (6.7%)       8 (6.1%)   
        Total number of patients with at least one non-fatal unresolved or ongoing AE   51 (38.1%)   51 (38.1%)     58 (43.9%)  
        Total number of patients with at least one serious AE                           38 (28.4%)   40 (29.9%)     45 (34.1%)  
        Total number of patients with at least one related AE                           36 (26.9%)   34 (25.4%)     36 (27.3%)  
      D.2.1.5.3/A.1.1.1.1 AESI                                                                                                  
        Total number of patients with at least one AE                                   62 (46.3%)   61 (45.5%)     76 (57.6%)  
        Total number of AEs                                                                106          100            139      
        Total number of patients with at least one AE by worst grade                                                            
          Grade 1                                                                       62 (46.3%)   61 (45.5%)     76 (57.6%)  
          Grade 2                                                                           0            0              0       
          Grade 3                                                                           0            0              0       
          Grade 4                                                                           0            0              0       
          Grade 5 (fatal outcome)                                                           0            0              0       
        Total number of patients with study drug withdrawn due to AE                     6 (4.5%)     8 (6.0%)       4 (3.0%)   
        Total number of patients with dose modified/interrupted due to AE               23 (17.2%)   20 (14.9%)     26 (19.7%)  
        Total number of patients with treatment received for AE                         33 (24.6%)   37 (27.6%)     33 (25.0%)  
        Total number of patients with all non-fatal AEs resolved                         4 (3.0%)     5 (3.7%)      14 (10.6%)  
        Total number of patients with at least one non-fatal unresolved or ongoing AE   58 (43.3%)   56 (41.8%)     62 (47.0%)  
        Total number of patients with at least one serious AE                               0            0              0       
        Total number of patients with at least one related AE                           37 (27.6%)   46 (34.3%)     50 (37.9%)  

